Anpu Biomedical

Anpu Biomedical is a Shanghai-based biotechnology company specializing in the early detection and screening of cancer through liquid biopsy and DNA methylation analysis. The company leverages its proprietary technology to develop non-invasive diagnostic tests for a variety of high-incidence cancers, including lung, liver, and gastrointestinal malignancies. By identifying specific epigenetic markers in blood samples, Anpu Biomedical aims to provide high-sensitivity and high-specificity screening tools that enable earlier intervention and improved patient outcomes. Their product portfolio includes both single-cancer and multi-cancer early detection (MCED) solutions currently being integrated into clinical and health examination settings.